Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
- 77 Downloads
The risk of potential drug–drug interactions (PDI) is poorly studied in oncology. We included 105 patients with advanced non-small-cell lung cancer (NSCLC), 100 patients with advanced breast cancer (BC) and 100 patients of the palliative care unit (PCU) receiving systemic palliative treatment between 2010 and 2015. All patients suffered from advanced incurable cancer and received basic palliative care. PDI were assessed using the hospINDEX of all drugs approved in Switzerland in combination with a specific drug interaction software. Primary study objective was to assess the prognostic impact of PDI per patient cohort using Kaplan–Meier statistics. The median number of comedications was 5 (range 0–15). Major-risk PDI were detected in 74 patients (24.3%). The number of comedications was significantly associated with PDI (p < 0.0001). Major-risk PDI increased from 14% in patients with < 4 comedications to 24% in patients with 4–7 comedications, 40% with 8–11 comedications and 67% in patients with > 11 comedications. Median overall survival (OS) was 8.6 months in NSCLC, 33 months in BC and 1.2 months in PCU patients. PDI were significantly associated with inferior OS in BC (HR = 1.32, 95% CI 1.01–1.74, p = 0.049), but not in NSCLC (HR = 1.11, 95% CI 0.84–1.47, p = 0.45) or PCU (HR = 1.12, 95% CI 0.86–1.45, p = 0.41). PDI remained significantly associated with OS in BC (HR = 1.32, p = 0.049) in the adjusted model. In conclusion, PDI are frequent in patients with advanced cancer and increased caution with polypharmacy is warranted when treating such patients.
KeywordsDrug safety Drug interactions Breast cancer Lung cancer Anticancer drugs
Compliance with ethical standards
Conflict of interest
The authors declare no competing interests concerning this work.
- 7.Yoshida K, Maeda K, Sugiyama Y (2013) Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug–drug interactions and genetic polymorphisms. Annu Rev Pharmacol Toxicol 53:581–612. https://doi.org/10.1146/annurev-pharmtox-011112-140309 CrossRefGoogle Scholar
- 14.Peters S, Zimmermann S, Adjei AA (2014) Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug–drug interactions. Cancer Treatm Rev 40(8):917–926. https://doi.org/10.1016/j.ctrv.2014.06.010 CrossRefGoogle Scholar
- 22.Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676–682. https://doi.org/10.1093/aje/kwq433 CrossRefGoogle Scholar
- 23.Karlen S, Eschmann E, Blaser J (2014) Entscheidungsunterstützung beim Medikamentenprozess: Wie umfangreich sind die hospINDEX-Stammdaten? Swiss Med Inf 30Google Scholar
- 28.Fernandez de Palencia Espinosa MA, Diaz Carrasco MS, Fuster Soler JL, Ruiz Merino G, De la Rubia Nieto MA, Espuny Miro A (2014) Pharmacoepidemiological study of drug–drug interactions in onco-hematological pediatric patients. Int J Clin Pharm 36(6):1160–1169. https://doi.org/10.1007/s11096-014-0011-1 CrossRefGoogle Scholar
- 34.Meek IL, Vonkeman HE, Kasemier J, Movig KL, van de Laar MA (2013) Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol 69(3):365–371. https://doi.org/10.1007/s00228-012-1370-y CrossRefGoogle Scholar